Qynapse
Qynapse, through QyScore, brings groundbreaking peace of mind to the global fight against CNS disease. Qyscore is a medical device software FDA-cleared – class II and CE-marked – class IIa (CE BSI). Qyscore is a medical device software FDA-cleared – class II and CE-marked – class IIa (CE BSI). QyScore is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases. QyScore has demonstrated superior performance compared to certain other automated state-of-the-art methods and has been validated against gold-standard manual segmentation. FDA-Cleared and CE-Marked, QyScore® will be expanding soon into new global markets.
Company details
Find locations served, office locations
- Business Type:
- Software vendor
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2015
About Us
For healthcare providers, pharma, payers and, above all, patients and their loved ones, Together, with our world-renowned team of scientific and clinical partners, Qynapse has developed one of the largest datasets of proprietary algorithms that rapidly, accurately and objectively analyze and interpret a brain scan.
To healthcare practitioners, we bring empowering, illuminating data.
To pharma and biotech, we bring reliable measurements which have the potential to impact clinical trial outcomes and the monitoring of therapies post-market.
To payers, QyScore® offers the possibility to drive down long-term healthcare costs, improve outcomes and improve patient satisfaction.
To patients and their loved ones, QyScore® provides MRI analyses to their healthcare providers that may help bring clarity and peace of mind.
Our technology is a game changer.
Our flagship solution, QyScore®, provides a large portfolio of automated measures of neuroinflammation and neurodegeneration, such as whole brain, white matter, grey matter by lobe, cerebellum, white matter abnormalities and brain substructures. QyScore® is used in clinical routine and clinical trial settings and is both comprehensive and scientifically based.
Our automated patient report and proprietary 3D visualization platform, provides physicians and pharma researchers a reliable layer of precision when reading an MRI scan, offering clarity to patients and their loved ones and setting out the potential for an expedited and improved to-market process for a larger number of CNS drug therapies.
Our Story
For healthcare providers, payers, pharma and, above all, patients and their loved ones, Qynapse brings groundbreaking peace of mind to the global fight against CNS disease. Founded in Paris, France in 2015, as a spin-off from the CATI consortium of neuroimaging research laboratories, Qynapse is on a mission to advance the accuracy and reliability of CNS disease screening and monitoring in both clinical routine settings and in clinical trial applications.
Our FDA-Cleared and CE-Marked neuroimaging software platform, QyScore®, produces a wide range of automated measures of neuroinflammation and neurodegeneration to support more accurate diagnosis in clinical care and imaging endpoints in a clinical trial setting. In clinical routine, QyScore® has the potential to support timely diagnosis, disease & therapy monitoring, tailored treatment plans and facilitate therapeutic switching. In a clinical trial setting, QyScore® has the potential to reduce reading variability in images, the potential to improve pre-identification of patients eligible for CNS trials, automates image pre-processing, quality control and image analysis, and the potential for better measurement of drug efficacy and safety.
Our predictive research use only platform QyPredict®, powered by machine learning algorithms is being developed to increase the possibility to predict a patient’s individual disease trajectory, which would transform and improve timely intervention and treatment plans, and drastically improve quality of life and outcomes.